硫代氨基脲锌(II)配合物抗增殖潜能的研究:设计、合成及结构参数的密度泛函理论研究。

IF 3.4 4区 医学 Q2 CHEMISTRY, MEDICINAL
ChemMedChem Pub Date : 2025-10-16 DOI:10.1002/cmdc.202500545
Shivendra K Pandey, Abhishek Kumar, Sushil K Gupta, Ajay Kumar, Manoj K Bharty
{"title":"硫代氨基脲锌(II)配合物抗增殖潜能的研究:设计、合成及结构参数的密度泛函理论研究。","authors":"Shivendra K Pandey, Abhishek Kumar, Sushil K Gupta, Ajay Kumar, Manoj K Bharty","doi":"10.1002/cmdc.202500545","DOIUrl":null,"url":null,"abstract":"<p><p>Zinc complexes have promising possibilities as medicines since they have better efficacy and lower toxicity. Herein, two ligands are synthesized based on hydrazine-1-carbothioamide with substituents having different electronic nature {nitro (HNPhHCT) and methoxy (HMoPhHCT)} and their respective Zn(II) complexes {[Zn(NPhHCT)<sub>2</sub>] and [Zn(MoPhHCT)<sub>2</sub>]}. They have been fully characterized via several spectroscopic techniques (IR, NMR, HRMS, UV-Vis studies) and DFT studies. In addition, ligands and their respective complexes are screened for their antiproliferative activity against three different cancer cell lines, namely HuT-78 (T-cell lymphoma), DL (Dalton's lymphoma), and MCF-7 (Breast cancer) cell lines. Among the two complexes, [Zn(MoPhHCT)<sub>2</sub>] is found to be most cytotoxic on all three cancer cell lines. In HuT-78 cells, [Zn(MoPhHCT)<sub>2</sub>] exhibited IC<sub>50</sub> value at ≈4 µM. Further, glucose and ROS estimation assays suggested that [Zn(MoPhHCT)<sub>2</sub>] shows antiproliferative activity against T lymphoma cells by inhibiting their glycolytic activity and apoptosis induction by increasing ROS production. A molecular docking study is performed against an antiapoptotic protein, BCL2 (PDB: 2O2F), that confirms its inhibitory response with a binding score of -8.34 kcal mol<sup>-1</sup>. Further, the expression of BCL2 at the protein level is found to be significantly inhibited in response to treatment with [Zn(MoPhHCT)<sub>2</sub>], as evident by the Western blot analysis results.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500545"},"PeriodicalIF":3.4000,"publicationDate":"2025-10-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Investigations on Antiproliferative Potential of Thiosemicarbazone Zn(II) Complexes: Design, Synthesis, and Density Functional Theory Studies on Structural Parameters.\",\"authors\":\"Shivendra K Pandey, Abhishek Kumar, Sushil K Gupta, Ajay Kumar, Manoj K Bharty\",\"doi\":\"10.1002/cmdc.202500545\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Zinc complexes have promising possibilities as medicines since they have better efficacy and lower toxicity. Herein, two ligands are synthesized based on hydrazine-1-carbothioamide with substituents having different electronic nature {nitro (HNPhHCT) and methoxy (HMoPhHCT)} and their respective Zn(II) complexes {[Zn(NPhHCT)<sub>2</sub>] and [Zn(MoPhHCT)<sub>2</sub>]}. They have been fully characterized via several spectroscopic techniques (IR, NMR, HRMS, UV-Vis studies) and DFT studies. In addition, ligands and their respective complexes are screened for their antiproliferative activity against three different cancer cell lines, namely HuT-78 (T-cell lymphoma), DL (Dalton's lymphoma), and MCF-7 (Breast cancer) cell lines. Among the two complexes, [Zn(MoPhHCT)<sub>2</sub>] is found to be most cytotoxic on all three cancer cell lines. In HuT-78 cells, [Zn(MoPhHCT)<sub>2</sub>] exhibited IC<sub>50</sub> value at ≈4 µM. Further, glucose and ROS estimation assays suggested that [Zn(MoPhHCT)<sub>2</sub>] shows antiproliferative activity against T lymphoma cells by inhibiting their glycolytic activity and apoptosis induction by increasing ROS production. A molecular docking study is performed against an antiapoptotic protein, BCL2 (PDB: 2O2F), that confirms its inhibitory response with a binding score of -8.34 kcal mol<sup>-1</sup>. Further, the expression of BCL2 at the protein level is found to be significantly inhibited in response to treatment with [Zn(MoPhHCT)<sub>2</sub>], as evident by the Western blot analysis results.</p>\",\"PeriodicalId\":147,\"journal\":{\"name\":\"ChemMedChem\",\"volume\":\" \",\"pages\":\"e202500545\"},\"PeriodicalIF\":3.4000,\"publicationDate\":\"2025-10-16\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"ChemMedChem\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/cmdc.202500545\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"CHEMISTRY, MEDICINAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500545","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0

摘要

锌配合物具有较好的疗效和较低的毒性,具有很好的药物应用前景。本文以具有不同电子性质取代基的肼-1-碳硫酰胺{硝基(HNPhHCT)和甲氧基(hmphhct)}及其各自的Zn(II)配合物{[Zn(NPhHCT)2]和[Zn(mphhct)2]}为基础,合成了两种配体。它们已经通过多种光谱技术(IR, NMR, HRMS, UV-Vis研究)和DFT研究进行了充分的表征。此外,还筛选了配体及其复合物对三种不同的癌细胞系,即HuT-78 (t细胞淋巴瘤)、DL(道尔顿淋巴瘤)和MCF-7(乳腺癌)细胞系的抗增殖活性。在这两种复合物中,[Zn(MoPhHCT)2]被发现对所有三种癌细胞系的细胞毒性最大。在ht -78细胞中,[Zn(MoPhHCT)2]在≈4µM时表现出IC50值。此外,葡萄糖和ROS测定表明,[Zn(mophct)2]通过增加ROS的产生抑制T淋巴瘤细胞的糖酵解活性和诱导细胞凋亡,从而显示出对T淋巴瘤细胞的抗增殖活性。一项针对抗凋亡蛋白BCL2 (PDB: 2O2F)的分子对接研究证实了其抑制作用,结合评分为-8.34 kcal mol-1。此外,Western blot分析结果表明,在蛋白水平上,BCL2的表达在[Zn(MoPhHCT)2]处理后被显著抑制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Investigations on Antiproliferative Potential of Thiosemicarbazone Zn(II) Complexes: Design, Synthesis, and Density Functional Theory Studies on Structural Parameters.

Zinc complexes have promising possibilities as medicines since they have better efficacy and lower toxicity. Herein, two ligands are synthesized based on hydrazine-1-carbothioamide with substituents having different electronic nature {nitro (HNPhHCT) and methoxy (HMoPhHCT)} and their respective Zn(II) complexes {[Zn(NPhHCT)2] and [Zn(MoPhHCT)2]}. They have been fully characterized via several spectroscopic techniques (IR, NMR, HRMS, UV-Vis studies) and DFT studies. In addition, ligands and their respective complexes are screened for their antiproliferative activity against three different cancer cell lines, namely HuT-78 (T-cell lymphoma), DL (Dalton's lymphoma), and MCF-7 (Breast cancer) cell lines. Among the two complexes, [Zn(MoPhHCT)2] is found to be most cytotoxic on all three cancer cell lines. In HuT-78 cells, [Zn(MoPhHCT)2] exhibited IC50 value at ≈4 µM. Further, glucose and ROS estimation assays suggested that [Zn(MoPhHCT)2] shows antiproliferative activity against T lymphoma cells by inhibiting their glycolytic activity and apoptosis induction by increasing ROS production. A molecular docking study is performed against an antiapoptotic protein, BCL2 (PDB: 2O2F), that confirms its inhibitory response with a binding score of -8.34 kcal mol-1. Further, the expression of BCL2 at the protein level is found to be significantly inhibited in response to treatment with [Zn(MoPhHCT)2], as evident by the Western blot analysis results.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
ChemMedChem
ChemMedChem 医学-药学
CiteScore
6.70
自引率
2.90%
发文量
280
审稿时长
1 months
期刊介绍: Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies. ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs. Contents ChemMedChem publishes an attractive mixture of: Full Papers and Communications Reviews and Minireviews Patent Reviews Highlights and Concepts Book and Multimedia Reviews.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信